Rolf Mller

List of Publications by Year in Descending Order

132 papers	12,822 citations	50 h-index	112 g-index
134 ext. papers	13,599 ext. citations	10.7 avg, IF	5.96 L-index

#	Paper	IF	Citations
132	The multicellular signalling network of ovarian cancer metastases. *Clinical and Translational Medicine*, **2021**, 11, e633	5.7	2
131	Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer. *Theranostics*, **2021**, 11, 1377-1395	12.1	6
130	Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion. *Molecular Oncology*, **2020**, 14, 2142-2162	7.9	7
129	Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. *Cell Death and Disease*, **2020**, 11, 249	9.8	37
128	Monitoring of tumor burden in vivo by optical imaging in a xenograft SCID mouse model: evaluation of two fluorescent proteins of the GFP-superfamily. *Acta Radiologica*, **2019**, 60, 315-326	2	1
127	Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. *Theranostics*, **2019**, 9, 6047-6062	12.1	25
126	Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. *Theranostics*, **2019**, 9, 6601-6617	12.1	21
125	Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma. *Frontiers in Oncology*, **2019**, 9, 1150	5.3	26
124	Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment. *Molecular Oncology*, **2019**, 13, 185-201	7.9	28
123	DYRK1B regulates Hedgehog-induced microtubule acetylation. *Cellular and Molecular Life Sciences*, **2019**, 76, 193-207	10.3	4
122	Prognosis of ovarian cancer is associated with effector memory CD8 T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. *OncoImmunology*, **2018**, 7, e1424672	7.2	45
121	Chromatin Binding of -REL and p65 Is Not Limiting for Macrophage Transcription During Immediate Suppression by Ovarian Carcinoma Ascites. *Frontiers in Immunology*, **2018**, 9, 1425	8.4	6
120	Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment. *Molecular and Cellular Proteomics*, **2018**, 17, 270-289	7.6	34
119	Tumour-associated missense mutations in the dMi-2 ATPase alters nucleosome remodelling properties in a mutation-specific manner. *Nature Communications*, **2018**, 9, 2112	17.4	23
118	Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure. *Trends in Cancer*, **2017**, 3, 137-148	12.5	61
117	PPARin human cancer. *Biochimie*, **2017**, 136, 90-99	4.6	25
116	Peroxisome proliferator-activated receptor-inhibits human neuroblastoma cell tumorigenesis by inducing p53- and SOX2-mediated cell differentiation. *Molecular Carcinogenesis*, **2017**, 56, 1472-1483	5	17

115	Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. *OncoImmunology*, **2017**, 6, e1339854	7.2	16
114	Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. *BMC Genomics*, **2017**, 18, 243	4.5	27
113	Antigen Loss Variants: Catching Hold of Escaping Foes. *Frontiers in Immunology*, **2017**, 8, 175	8.4	20
112	The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. *Frontiers in Oncology*, **2017**, 7, 24	5.3	123
111	Shipping Drug Resistance: Extracellular Vesicles in Ovarian Cancer. *Trends in Molecular Medicine*, **2016**, 22, 741-743	11.5	8
110	A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. *Genome Biology*, **2016**, 17, 108	18.3	64
109	The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization. *Oncotarget*, **2016**, 7, 75339-75352	3.3	61
108	Design and Synthesis of Highly Active Peroxisome Proliferator-Activated Receptor (PPAR) Inverse Agonists with Prolonged Cellular Activity. *ChemMedChem*, **2016**, 11, 488-96	3.7	5
107	Establishing the Role of PPAR In Carcinogenesis. *Trends in Endocrinology and Metabolism*, **2015**, 26, 595-607	8.8	56
106	Peroxisome Proliferator-activated Receptor-D (PPARD) Coordinates Mouse Spermatogenesis by Modulating Extracellular Signal-regulated Kinase (ERK)-dependent Signaling. *Journal of Biological Chemistry*, **2015**, 290, 23416-31	5.4	13
105	The transcriptional PPAR network in human macrophages defines a unique agonist-induced activation state. *Nucleic Acids Research*, **2015**, 43, 5033-51	20.1	44
104	AMP-Activated Protein Kinase Interacts with the Peroxisome Proliferator-Activated Receptor Delta to Induce Genes Affecting Fatty Acid Oxidation in Human Macrophages. *PLoS ONE*, **2015**, 10, e0130893	3.7	13
103	The inverse agonist DG172 triggers a PPAR independent myeloid lineage shift and promotes GM-CSF/IL-4-induced dendritic cell differentiation. *Molecular Pharmacology*, **2015**, 87, 162-73	4.3	5
102	Deregulation of PPAR target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. *Oncotarget*, **2015**, 6, 13416-33	3.3	58
101	A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. *Oncotarget*, **2015**, 6, 40005-25	3.3	50
100	Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. *International Journal of Cancer*, **2014**, 134, 32-42	7.5	168
99	In vivo studies of PPAR-chromatin interactions: chromatin immunoprecipitation for single-locus and genomewide analyses. *Methods in Molecular Biology*, **2013**, 952, 175-85	1.4	4
98	PRMT4 is a novel coactivator of c-Myb-dependent transcription in haematopoietic cell lines. *PLoS Genetics*, **2013**, 9, e1003343	6	18

97	Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion. *Oncogene*, **2013**, 32, 5241-52	9.2	64
96	Regulation of TAK1/TAB1-mediated IL-1β signaling by cytoplasmic PPARβ/δ. *PLoS ONE*, **2013**, 8, e63011	3.7	13
95	Development of improved PPARβ/δ inhibitors. *ChemMedChem*, **2012**, 7, 159-70	3.7	25
94	(Z)-2-(2-bromophenyl)-3-{[4-(1-methyl-piperazine)amino]phenyl}acrylonitrile (DG172): an orally bioavailable PPARβ/δ selective ligand with inverse agonistic properties. *Journal of Medicinal Chemistry*, **2012**, 55, 2858-68	8.3	34
93	High-affinity peroxisome proliferator-activated receptor β/δ-specific ligands with pure antagonistic or inverse agonistic properties. *Molecular Pharmacology*, **2011**, 80, 828-38	4.3	32
92	Reverse crosstalk of TGFβ and PPARβ/δ signaling identified by transcriptional profiling. *Nucleic Acids Research*, **2011**, 39, 119-31	20.1	31
91	Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). *PLoS ONE*, **2011**, 6, e16344	3.7	61
90	15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist. *Molecular Pharmacology*, **2010**, 77, 171-84	4.3	70
89	Transcriptional profiling identifies functional interactions of TGF β and PPAR β/δ signaling: synergistic induction of ANGPTL4 transcription. *Journal of Biological Chemistry*, **2010**, 285, 29469-79	5.4	48
88	Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. *Molecular Pharmacology*, **2010**, 78, 419-30	4.3	45
87	The rotamase Pin1 is up-regulated, hypophosphorylated and required for cell cycle progression in head and neck squamous cell carcinomas. *Oral Oncology*, **2009**, 45, e140-9	4.4	10
86	Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. *Molecular Pharmacology*, **2008**, 74, 1269-77	4.3	54
85	Regulation of Cell Proliferation and Differentiation by PPARbeta/delta. *PPAR Research*, **2008**, 2008, 614852	4.3	19
84	A Role for PPARbeta/delta in Tumor Stroma and Tumorigenesis. *PPAR Research*, **2008**, 2008, 534294	4.3	10
83	Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-beta/delta gene. *Proteomics*, **2007**, 7, 1208-16	4.8	15
82	Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. *EMBO Journal*, **2007**, 26, 3686-98	13	85
81	Expression level and agonist-binding affect the turnover, ubiquitination and complex formation of peroxisome proliferator activated receptor beta. *FEBS Journal*, **2007**, 274, 5068-76	5.7	12
80	Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta. *Journal of Molecular Biology*, **2007**, 372, 341-55	6.5	74

79	Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene. *International Journal of Oncology*, **2007**, 31, 607-11	1	13
78	Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. *Journal of Immunotherapy*, **2006**, 29, 294-305	5	37
77	Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARbeta. *FEBS Journal*, **2006**, 273, 170-9	5.7	26
76	Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. *Oncogene*, **2005**, 24, 4301-10	9.2	76
75	Engineering of human coagulation factor x variants activated by prostate-specific antigen. *Molecular Biotechnology*, **2005**, 29, 19-30	3	
74	The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. *Journal of Biological Chemistry*, **2005**, 280, 4025-8	5.4	44
73	Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. *Protein Engineering, Design and Selection*, **2004**, 17, 433-41	1.9	100
72	Crosstalk of oncogenic and prostanoid signaling pathways. *Journal of Cancer Research and Clinical Oncology*, **2004**, 130, 429-44	4.9	38
71	Encapsulation of gadobutrol in AVE-based liposomal carriers for MR detectability. *Magnetic Resonance Imaging*, **2004**, 22, 483-7	3.3	9
70	Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. *Journal of Gene Medicine*, **2004**, 6, 642-51	3.5	50
69	Rational design of a bimodular model system for the investigation of heterocyclization in nonribosomal peptide biosynthesis. *Chemistry and Biology*, **2004**, 11, 261-71		48
68	Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). *Biochimica Et Biophysica Acta - Biomembranes*, **2004**, 1663, 158-66	3.8	51
67	Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library. *Biochemical and Biophysical Research Communications*, **2004**, 317, 515-21	3.4	25
66	Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. *Oncogene*, **2004**, 23, 6845-53	9.2	129
65	Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. *Journal of Immunotherapy*, **2004**, 27, 99-106	5	24
64	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. *Blood*, **2004**, 103, 3480-9	2.2	94
63	Isolation from phage display libraries of lysine-deficient human epidermal growth factor variants for directional conjugation as targeting ligands. *Protein Engineering, Design and Selection*, **2003**, 16, 1107-13	1.9	15
62	An advanced strategy of enhanced specific gene expression for hepatocellular carcinoma **2003**, 22, 1051		2

61	C-Raf controlled pathways in the protection of tumor cells from apoptosis. *International Journal of Cancer*, **2003**, 104, 425-32	7.5	8
60	Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F. *Oncogene*, **2003**, 22, 4943-52	9.2	17
59	Chimeric transcriptional control units for improved liver-specific transgene expression. *Gene*, **2003**, 322, 137-43	3.8	29
58	In vivo pro-apoptotic and antitumor efficacy of a c-Raf antisense phosphorothioate oligonucleotide: relationship to tumor size. *Oligonucleotides*, **2002**, 12, 11-20		8
57	A new colloidal lipidic system for gene therapy. *Journal of Liposome Research*, **2002**, 12, 37-44	6.1	15
56	Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles. *Journal of Gene Medicine*, **2001**, 3, 353-61	3.5	20
55	Highly efficient transduction of endothelial cells by targeted artificial virus-like particles. *Cancer Gene Therapy*, **2001**, 8, 107-17	5.4	42
54	Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. *European Journal of Cell Biology*, **2001**, 80, 99-110	6.1	119
53	Cell cycle regulation of the murine cdc25B promoter: essential role for nuclear factor-Y and a proximal repressor element. *Journal of Biological Chemistry*, **2001**, 276, 9662-9	5.4	33
52	Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. *Protein Engineering, Design and Selection*, **2001**, 14, 815-23	1.9	47
51	Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). *Molecular Therapy*, **2001**, 3, 882-91	11.7	112
50	Endothelial-like cells derived from human CD14 positive monocytes. *Differentiation*, **2000**, 65, 287-300	3.5	303
49	Gene therapy: designer promoters for tumour targeting. *Trends in Genetics*, **2000**, 16, 174-81	8.5	196
48	Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. *Journal of Biological Chemistry*, **2000**, 275, 32089-97	5.4	48
47	In vivo structure of the cell cycle-regulated human cdc25C promoter. *Journal of Biological Chemistry* , **2000**, 275, 18676-81	5.4	6
46	The activity of the murine Bax promoter is regulated by Sp1/3 and E-box binding proteins but not by p53. *Cell Death and Differentiation*, **1999**, 6, 873-82	12.7	45
45	The SV40 large T oncoprotein disrupts DNA-binding of the cell cycle-regulated transcriptional repressor CDF. *Oncogene*, **1999**, 18, 2023-5	9.2	6
44	Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation. *Oncogene*, **1999**, 18, 19-25	9.2	40

43	Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation. *Oncogene*, **1999**, 18, 5620-30	9.2	99
42	Cell type specificity of the human endoglin promoter. *Gene*, **1999**, 227, 55-62	3.8	50
41	Elevated expression of endoglin, a component of the TGF-β receptor complex, correlates with proliferation of tumor endothelial cells **1999**, 81, 568		2
40	Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells. *Human Gene Therapy*, **1998**, 9, 2653-9	4.8	29
39	Abrogation of c-Raf expression induces apoptosis in tumor cells. *Oncogene*, **1998**, 16, 1899-902	9.2	65
38	A new model of cell cycle-regulated transcription: repression of the cyclin A promoter by CDF-1 and anti-repression by E2F. *Oncogene*, **1998**, 16, 2957-63	9.2	73
37	Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells. *International Journal of Cancer*, **1998**, 77, 146-52	7.5	69
36	Cell cycle regulated promoters for the targeting of tumor endothelium. *Advances in Experimental Medicine and Biology*, **1998**, 451, 437-40	3.6	3
35	Use of conditional promoters for expression of heterologous proteins in Saccharomyces cerevisiae. *Methods in Enzymology*, **1997**, 283, 313-22	1.7	32
34	Cell-cycle regulation of gene expression by transcriptional repression. *Trends in Genetics*, **1997**, 13, 3-6	8.5	96
33	Cloning and functional expression of glycosyltransferases from parasitic protozoans by heterologous complementation in yeast: the dolichol phosphate mannose synthase from Trypanosoma brucei brucei. *Biochemical Journal*, **1996**, 316 (Pt 3), 853-8	3.8	46
32	Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. *Journal of Biological Chemistry*, **1996**, 271, 20608-16	5.4	978
31	Cell cycle regulation of cdc25C transcription is mediated by the periodic repression of the glutamine-rich activators NF-Y and Sp1. *Nucleic Acids Research*, **1995**, 23, 3822-30	20.1	94
30	Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene*, **1995**, 156, 119-22	3.8	1587
29	Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation. *Experimental Cell Research*, **1995**, 219, 527-35	4.2	52
28	Transcriptional regulation during the mammalian cell cycle. *Trends in Genetics*, **1995**, 11, 173-8	8.5	149
27	Different fate of sibling cells upon inhibition of transcription in G1. *Experimental Cell Research*, **1994**, 210, 349-52	4.2	
26	Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression. *Nucleic Acids Research*, **1994**, 22, 5767-8	20.1	808

25	Signals and genes in the control of cell-cycle progression. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1993**, 1155, 151-79	11.2	23
24	Multiple interdependent regulatory sites in the mouse c-fos promoter determine basal level transcription: cell type-specific effects. *Nucleic Acids Research*, **1991**, 19, 3583-91	20.1	21
23	Non-leucine residues in the leucine repeats of Fos and Jun contribute to the stability and determine the specificity of dimerization. *Nucleic Acids Research*, **1991**, 19, 739-46	20.1	79
22	Two functionally different regions in Fos are required for the sequence-specific DNA interaction of the Fos/Jun protein complex. *Nature*, **1989**, 338, 589-90	50.4	153
21	A Fos protein containing the Jun leucine zipper forms a homodimer which binds to the AP1 binding site. *Nature*, **1989**, 341, 243-5	50.4	64
20	trans-repression of the mouse c-fos promoter: a novel mechanism of Fos-mediated trans-regulation. *Cell*, **1989**, 59, 999-1007	56.2	172
19	The leucine repeat motif in Fos protein mediates complex formation with Jun/AP-1 and is required for transformation. *Cell*, **1989**, 56, 507-16	56.2	293
18	Chromatin association and DNA binding properties of the c-fos proto-oncogene product. *Nucleic Acids Research*, **1987**, 15, 277-92	20.1	64
17	Involvement of common and cell type-specific pathways in c-fos gene control: stable induction of cAMP in macrophages. *Cell*, **1987**, 48, 251-60	56.2	214
16	Deregulated c-fos expression interferes with normal bone development in transgenic mice. *Nature*, **1987**, 325, 412-6	50.4	328
15	Lineage-specific expression of c-fos and c-fms in human hematopoietic cells: discrepancies with the in vitro differentiation of leukemia cells. *Differentiation*, **1986**, 33, 56-60	3.5	22
14	Cellular and viral fos genes: structure, regulation of expression and biological properties of their encoded products. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1986**, 823, 207-25	11.2	32
13	Induction of c-fos during myelomonocytic differentiation and macrophage proliferation. *Nature*, **1985**, 314, 546-8	50.4	297
12	Persistence of the competent state in mouse fibroblasts is independent of c-fos and c-myc expression. *Experimental Cell Research*, **1985**, 160, 540-3	4.2	20
11	Differentiation of F9 teratocarcinoma stem cells after transfer of c-fos proto-oncogenes. *Nature*, **1984**, 311, 438-42	50.4	283
10	Induction of c-fos gene and protein by growth factors precedes activation of c-myc. *Nature*, **1984**, 312, 716-20	50.4	1302
9	Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. *Cell*, **1983**, 32, 1241-55	56.2	536
8	Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. *Methods in Enzymology*, **1983**, 92, 589-601	1.7	90

7	Similar rate of O6-ethylguanine elimination from DNA in normal human fibroblast and xeroderma pigmentosum cell strains not transformed by SV40. *Carcinogenesis*, **1983**, 4, 1075-7	4.6	12
6	Enzymatic removal of O6-ethylguanine versus stability of O4-ethylthymine in the DNA of rat tissues exposed to the carcinogen ethylnitrosourea: possible interference of guanine-O6 alkylation with 5-cytosine methylation in the DNA of replicating target cells. *Zeitschrift Fur Naturforschung - Section C Journal of Biosciences*, **1983**, 38, 1023-9	1.7	21
5	Tissue and cell type-specific expression of two human c-onc genes. *Nature*, **1983**, 304, 454-6	50.4	169
4	Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. *Nature*, **1982**, 299, 640-4	50.4	529
3	Enzymatic synthesis of double-stranded DNA containing radioactively labeled O(6)-ethylguanine as the only modified base. *Carcinogenesis*, **1981**, 2, 321-7	4.6	8
2	Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay. *Journal of Immunological Methods*, **1980**, 34, 345-52	2.5	128
1	Sensitive radioimmunoassay for detection of O6-ethyldeoxyguanosine in DNA exposed to the carcinogen ethylnitrosourea in vivo or in vitro. *Zeitschrift Fur Naturforschung - Section C Journal of Biosciences*, **1978**, 33, 897-901	1.7	31